Detalhe da pesquisa
1.
Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression.
Future Oncol
; 16(28): 2177-2189, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32716216
2.
The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers.
PLoS One
; 13(10): e0206007, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30335866
3.
PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.
Oncotarget
; 9(19): 14922-14938, 2018 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-29599916